https://sareum.com/chairmans-corner/publications/immunotherapeutic-effects-of-the-tyk2-inhibitor-sar-20351-in-syngeneic-tumour-models/2023-03-20T16:15:38+00:00https://sareum.com/chairmans-corner/publications/inhibition-of-tyk2-and-jak1-ameliorates-imiquimod-induced-psoriasis-like-dermatitis-by-inhibiting-il-22-and-the-il-23-il-17-axis/2023-03-20T16:17:11+00:00https://sareum.com/chairmans-corner/publications/a-new-regulatory-switch-in-a-jak-protein-kinase/2023-03-20T16:18:46+00:00https://sareum.com/chairmans-corner/publications/a-phase-i-ii-trial-of-oral-sra737-a-chk1-inhibitor-given-in-combination-with-low-dose-gemcitabine-in-patients-with-advanced-cancer/2023-11-29T14:32:47+00:00https://sareum.com/chairmans-corner/publications/a-study-of-combinatorial-growth-inhibition-cell-death-and-dna-damage-repair-caused-by-chk1-inhibitor-sra737-and-wee1-inhibitor-adavosertib-in-tp53-mutated-cell-line/2023-03-20T16:26:20+00:00https://sareum.com/chairmans-corner/publications/chk1-inhibition-is-synthetically-lethal-with-loss-of-b-family-dna-polymerase-function-in-human-lung-and-colorectal-cancer-cells/2023-03-20T16:29:05+00:00https://sareum.com/chairmans-corner/publications/combination-treatment-of-the-oral-chk1-inhibitor-sra737-and-low-dose-gemcitabine-enhances-the-effect-of-pd-l1-blockade-by-modulating-the-immune-microenvironment-in-small-cell-lung-cancer/2023-03-20T16:31:07+00:00https://sareum.com/chairmans-corner/publications/the-chk1-inhibitor-sra737-synergizes-with-parp1-inhibitors-to-kill-carcinoma-cells/2023-03-20T16:33:18+00:00https://sareum.com/chairmans-corner/publications/an-orally-bioavailable-chk1-inhibitor-cct244747-sensitizes-bladder-and-head-and-neck-cancer-cell-lines-to-radiation/2023-03-20T16:34:38+00:00https://sareum.com/chairmans-corner/publications/dna-replication-stress-mediates-apobec3-family-mutagenesis-in-breast-cancer/2023-03-20T16:37:09+00:00https://sareum.com/chairmans-corner/publications/chk1-inhibition-radiosensitises-head-and-neck-cancers-to-paclitaxel-based-chemoradiotherapy/2023-03-20T16:38:57+00:00https://sareum.com/chairmans-corner/publications/multi-parameter-lead-optimization-to-give-an-oral-checkpoint-kinase-1-chk1-inhibitor-clinical-candidate-r-5-4-morpholin-2-ylmethylamino-5-trifluoromethylpyridin-2-ylaminopyrazine-2-carb/2023-03-20T16:40:36+00:00https://sareum.com/chairmans-corner/publications/the-clinical-development-candidate-cct245737-is-an-orally-active-chk1-inhibitor-with-preclinical-activity-in-ras-mutant-nsclc-and-e%c2%b5-myc-driven-b-cell-lymphoma/2023-03-20T16:41:43+00:00https://sareum.com/chairmans-corner/publications/targeted-radiosensitization-by-the-chk1-inhibitor-sar-020106/2023-03-20T16:42:40+00:00https://sareum.com/chairmans-corner/publications/structure-based-design-discovery-and-development-of-checkpoint-kinase-inhibitors-as-potential-anticancer-therapies/2023-03-20T16:45:37+00:00https://sareum.com/chairmans-corner/publications/cct244747-is-a-novel-potent-and-selective-chk1-inhibitor-with-oral-efficacy-alone-and-in-combination-with-genotoxic-anticancer-drugs/2023-03-20T16:47:03+00:00https://sareum.com/chairmans-corner/publications/discovery-of-3-alkoxyamino-5-pyridin-2-ylamino-pyrazine-2-carbonitriles-as-selective-orally-bioavailable-chk1-inhibitors/2023-03-20T16:48:44+00:00https://sareum.com/chairmans-corner/publications/structure-guided-evolution-of-potent-and-selective-chk1-inhibitors-through-scaffold-morphing/2023-03-20T16:50:12+00:00https://sareum.com/chairmans-corner/publications/cct244747-is-a-novel-potent-and-selective-inhibitor-of-chk1-with-oral-efficacy-both-alone-in-neuroblastoma-and-in-combination-with-genotoxic-chemotherapeutic-agents/2023-03-20T16:57:33+00:00https://sareum.com/chairmans-corner/publications/structure-guided-evolution-of-potent-and-selective-chk1-inhibitors-through-scaffold-morphing-2/2023-03-20T16:58:31+00:00https://sareum.com/chairmans-corner/publications/design-and-evaluation-of-36-diheteroaryl-imidazo12-apyrazines-as-inhibitors-of-checkpoint-and-other-kinases/2023-03-20T16:59:45+00:00https://sareum.com/chairmans-corner/publications/the-preclinical-pharmacology-and-therapeutic-activity-of-the-novel-chk1-inhibitor-sar-020106/2023-03-20T17:02:40+00:00https://sareum.com/chairmans-corner/publications/identification-of-inhibitors-of-checkpoint-kinase-1-through-template-screening/2023-03-20T17:03:32+00:00https://sareum.com/chairmans-corner/publications/identification-and-structure-guided-optimisation-of-novel-inhibitors-of-checkpoint-kinase-1-chk1-through-combined-biochemical-and-crystallographic-screening/2023-03-20T17:04:55+00:00https://sareum.com/chairmans-corner/publications/a-phase-i-ii-trial-of-oral-sra737-a-chk1-inhibitor-given-in-combination-with-low-dose-gemcitabine-in-patients-with-advanced-cancer-2/2025-03-26T11:06:38+00:00https://sareum.com/chairmans-corner/publications/a-phase-i-ii-trial-of-oral-sra737-a-chk1-inhibitor-given-in-combination-with-low-dose-gemcitabine-in-patients-with-advanced-cancer-2-2/2026-03-10T15:15:12+00:00https://sareum.com/chairmans-corner/publications/a-phase-i-ii-trial-of-oral-sra737-a-chk1-inhibitor-given-in-combination-with-low-dose-gemcitabine-in-patients-with-advanced-cancer-2-2-2/2026-04-09T14:34:52+00:00